About the Company
We do not have any company description for Cidara Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Good afternoon, and welcome to the Cidara Therapeutics Second ...
Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout
Cidara Therapeutics, Inc.'s CD388 shows promise as a superior flu prophylactic. Click for strong trial results, upcoming ...
Cidara Therapeutics: Promising Trials Amidst Financial Challenges
Cidara Therapeutics Inc. (($CDTX)) has held its Q2 earnings call. Read on for the main highlights of the call. Cidara Therapeutics Inc. recently ...
Cidara Therapeutics Inc (CDTX) Q2 2025 Earnings Call Highlights: Promising Clinical Trial ...
Cidara Therapeutics Inc (CDTX) reports significant progress in influenza prevention trials and secures substantial funding, ...
Cidara Therapeutics Announces FDA Acceptance of its ... - Nasdaq
--Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that the U.S ...
Cidara Therapeutics Provides Corporate Update and Reports Fourth ...
As of December 31, 2023, Cidara had 90,601,999 shares of common stock outstanding, and 2,104,472 shares of Series X Convertible Preferred Stock outstanding, which are convertible into 21,044,720 ...
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc ...
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC ...
Cidara Therapeutics: Q1 Earnings Snapshot - The Washington Post
SAN DIEGO — SAN DIEGO — Cidara Therapeutics Inc. (CDTX) on Thursday reported a loss of $23.5 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss ...
Cidara Therapeutics Provides Update on Status of Ongoing CD388 ...
--Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today provided an ...
Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a ...
SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate ...
Cidara Therapeutics, Inc. (CDTX) Q1 2025 Earnings Call Transcript
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ETCompany ParticipantsBrian Ritchie - LifeSci AdvisorsJeffrey ...
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Q1 2025 Earnings Call ...
Cidara Therapeutics, Inc. undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call.
Similar Companies
Loading the latest forecasts...